Role of tranexamic acid as an adjunctive for chronic sub dural hematoma for early resolution and reduced recurrence rate: a prospective case-control study
DOI:
https://doi.org/10.18203/2349-2902.isj20243460Keywords:
Tranexamic acid, CDSH, Case-control study, South IndiaAbstract
Background: Literature shows the effective use of tranexamic acid to reduce CSDH either as a primary treatment or as an adjunctive treatment. However, literature lacks conclusive evidence on the use of tranexamic acid for CSDH. There are not many Indian studies also on this subject. This study was aimed at finding the effectiveness of tranexamic acid in reducing the recurrence rate following surgery and early resolution.
Methods: From May 2023 to May 2024, single centric case control study was done in a tertiary care center (Government Mohan Kumaramangalam medical college hospital, Salem) in Southern India. All patients with chronic subdural hematoma with Markwalder grading 2-4 and grade 1 with midline shift more than 1 cm were included in the study. Patients with severe cardio-cerebrovascular disease, patients with allergy to tranexamic acid and patients not willing to participate were excluded from the study. Tranexamic acid was given at a dose of 500 mg twice a day for 10 days. Patients were allocated into two groups: group A: where tranexamic acid was used, group B: where tranexamic acid was not used.
Results: The mean duration of hospital stay was lesser in tranexamic acid group (p<0.005). The mean SDH thickness was lesser at 4th and 8th week in tranexamic acid group (p<0.005). Recurrence rate was lesser in tranexamic acid group at three months (p>0.05).
Conclusions: This study of patients with CSDH showed that the adjunctive use of TXA after burr-hole drainage is effective in achieving resolution of CSDH through faster hematoma reduction. TXA may have a favorable effect in reducing recurrence and can be administered safely in selected patients.
References
Cofano F, Pesce A, Vercelli G, Mammi M, Massara A, Minardi M, et al. Risk of recurrence of chronic subdural hematomas after surgery: a multicenter observational cohort study. Front Neurol. 2020;11:560269.
Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KL, Hutchinson PJ. Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy. J Neuroinflammation. 2017;14:1-13.
Edlmann E, Holl DC, Lingsma HF, Bartek J, Bartley A, Duerinck J, et al. Systematic review of current randomised control trials in chronic subdural haematoma and proposal for an international collaborative approach. Acta Neurochirurgica, 2020;162:763-76.
Holl DC, Volovici V, Dirven CM, Peul WC, Van Kooten F, Jellema K, et al. Pathophysiology and nonsurgical treatment of chronic subdural hematoma: from past to present to future. World neurosurgery. 2018;116:402-11.
Huang J, Gao C, Dong J, Zhang J, Jiang R. Drug treatment of chronic subdural hematoma. Expert opinion on pharmacotherapy, 2020;21(4):435-44.
Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. Nature Reviews Neurol. 2014;10(10):570-8.
Lee KS. How to treat chronic subdural hematoma? Past and now. J Korean Neurosurgical Society. 2019;62(2):144-52.
Iorio-Morin C, Blanchard J, Richer M, Mathieu D. Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial. Trials. 2016;17:1-11.
Kageyama H, Toyooka T, Tsuzuki N, Oka K. Nonsurgical treatment of chronic subdural hematoma with tranexamic acid. J Neurosurg. 2013;119(2):332-7.
Kutty RK, Peethambaran AK, Sunilkumar, Anilkumar M. Conservative treatment of chronic subdural hematoma in HIV-associated thrombocytopenia with tranexamic acid. J Int Assoc Providers AIDS Care. 2017;16(3):211-4.
Lodewijkx R, Immenga S, van den Berg R, Post R, Westerink LG, Nabuurs RJ, et al. Tranexamic acid for chronic subdural hematoma. Brit J Neurosurg. 2021;35(5):564-9.
Wan KR, Qiu L, Saffari SE, Khong WXL, Ong JCL, See AA, et al. An open label randomized trial to assess the efficacy of tranexamic acid in reducing post-operative recurrence of chronic subdural haemorrhage. J Clin Neurosci. 2020;82:147-54.
Yamada T, Natori Y. Prospective study on the efficacy of orally administered tranexamic acid and goreisan for the prevention of recurrence after chronic subdural hematoma burr hole surgery. World neurosur. 2020;134:e549-53.
Wang X, Song J, He Q, You C. Pharmacological treatment in the management of chronic subdural hematoma. Front Aging neurosci. 2021;13:684501.
